Pulmonary Embolism Imaging: CT Angiogram for Life-Threatening PE

Sudden shortness of breath, chest pain, and rapid breathing—pulmonary embolism (PE) kills quickly if untreated. CT pulmonary angiogram (CTPA) detects pulmonary emboli within minutes, becoming the gold standard for diagnosing this emergency. Understanding when to suspect PE, what CTPA shows, and how results guide treatment can save lives.

CT pulmonary angiogram (CTPA) is the first-line imaging test for suspected pulmonary embolism in most patients. CTPA detects clots in the pulmonary arteries with sensitivity >95% and specificity >95%, providing rapid diagnosis that guides immediate anticoagulation or thrombolytic therapy.

Alternative: V/Q Scan (ventilation-perfusion) is used when:

• CT contrast contraindicated (severe allergy, kidney failure)
• Young patients (radiation concerns)
• Pregnancy (lower radiation than CTPA)
• Baseline abnormal chest X-ray (certain patterns)

”

Clinical Guideline: The American College of Radiology gives CTPA a rating of "9" (usually appropriate) for initial evaluation of suspected acute pulmonary embolism. V/Q scan receives a rating of "6" (may be appropriate) for specific scenarios.

Source: ACR Appropriateness Criteria®® - Suspected Pulmonary Embolism Date: 2023

What Is Pulmonary Embolism?

Pathophysiology:

• Deep vein thrombosis (DVT): Blood clot forms in deep veins (usually legs)
• Clot migration: Clot breaks off, travels through venous system
• Pulmonary artery occlusion: Lodges in pulmonary arteries, blocking blood flow
• Right heart strain: Right ventricle must pump against increased resistance
• Ventilation-perfusion mismatch: Lung segments ventilated but not perfused

Epidemiology:

• Incidence: 60-100 per 100,000 population annually
• Mortality (untreated): Up to 30%
• Mortality (treated): 2-8% (higher with massive PE)
• Recurrence: 5-10% after stopping anticoagulation
• Age: Most common in ages 60-80

”

Clinical Reality: PE is often called "the great masquerader" because symptoms can mimic many other conditions—pneumonia, myocardial infarction, pleurisy, anxiety. High clinical suspicion is essential for prompt diagnosis.

Source: New England Journal of Medicine - Pulmonary Embolism: Diagnosis and Management Date: 2022

PE Severity Classification

Risk Stratification (based on hemodynamics and imaging):

”

Key Point: CT doesn't just diagnose PE—it also stratifies risk by showing right ventricular strain. This information determines whether patients get standard anticoagulation or more aggressive thrombolytic therapy.

Source: European Heart Journal - Risk Stratification in Acute Pulmonary Embolism Date: 2021

Clinical Presentation

Classic Symptoms (unfortunately insensitive and nonspecific):

• Dyspnea: Sudden onset, progressive (present in >80%)
• Pleuritic chest pain: Sharp, worse with inspiration (50-70%)
• Tachycardia: Heart rate >100 bpm (40-50%)
• Tachypnea: Respiratory rate >20/min (60-70%)
• Cough: Usually dry, sometimes hemoptysis (20-30%)
• Hemoptysis: Blood-tinged sputum (10-20%)

Less Common Presentations:

• Syncope (fainting): Especially with massive PE
• Palpitations: Irregular heartbeat from right heart strain
• Lower extremity symptoms: DVT signs in 30-50% (swelling, pain, redness)
• Fever: Low-grade (38-39°C), mimics infection
• Apprehension: Sense of doom or impending death

Physical Exam Findings:

• Tachycardia (most common sign)
• Tachypnea (second most common)
• Loud P2: Pulmonic valve component loud from pulmonary hypertension
• Right ventricular heave: Palpable impulse from right heart strain
• Lower extremity DVT signs: Asymmetric swelling, tenderness, erythema

”

Clinical Challenge: No single symptom or sign confirms or excludes PE. The pre-test probability (Wells or Geneva score) guides whether imaging is warranted.

Source: JAMA - Diagnostic Value of Clinical Findings for Pulmonary Embolism Date: 2021

Risk Factors for PE

Provoking Factors (Transient):

• Recent surgery (especially orthopedic): 20-100x increased risk
• Trauma: Fractures (pelvis, femur), major injuries
• Immobilization: >3 days (hospitalization, long travel)
• Pregnancy: 5-10x increased risk, highest postpartum
• Oral contraceptives/hormone therapy: 2-4x increased risk
• Active cancer: 4-7x increased risk

Persistent Risk Factors:

• Previous VTE: 5-10x increased risk of recurrence
• Cancer: Ongoing risk, especially with chemotherapy
• Obesity (BMI >30): 2-3x increased risk
• Inherited thrombophilia: Factor V Leiden, prothrombin mutation
• Chronic medical conditions: Heart failure, COPD, inflammatory bowel disease

”

Clinical Insight: Having multiple risk factors dramatically increases risk. A patient with cancer, recent surgery, and immobility has exponentially higher risk than any single factor alone.

Source: Chest - Risk Factors for Venous Thromboembolism Date: 2022

Pre-Test Probability Scoring

Wells Criteria for PE (most commonly used):

Interpretation:

• Score ≤4: Low probability (PE unlikely)
• Score >4, ≤10: Moderate probability
• Score >10: High probability (PE likely)

Diagnostic Algorithm:

Suspected PE
↓
Calculate Wells score
↓
Low probability (≤4) + High D-dimer → Treat as PE
Low probability + Low D-dimer → PE excluded (no imaging)
Moderate/High probability → CT pulmonary angiogram regardless of D-dimer

”

Clinical Practice: Most clinicians proceed directly to CTPA for moderate/high pre-test probability. D-dimer is most useful in low-probability patients to exclude PE (high negative predictive value).

Source: Annals of Internal Medicine - Derivation of the Revised Geneva Score Date: 2021

How CTPA Works

Technique:

1. Patient positioning: Supine, arms above head
2. Scout scan: Localizer image for planning
3. Contrast injection: 60-80 mL iodinated contrast via power injector (4-5 mL/sec)
4. Bolus tracking: Automatic trigger when contrast reaches pulmonary arteries
5. Scan acquisition: Craniocaudal (from lung apices to diaphragm)
6. Breath-hold: Single breath-hold (5-10 seconds)
7. Reconstruction: Thin slices (0.625-1.25 mm) for multiplanar reconstruction

Total time: 5-10 minutes (including positioning, injection, scan)

”

Technical Advance: Modern 128- to 320-slice CT scanners acquire the entire chest in 1-3 seconds during a single breath-hold, virtually eliminating motion artifact and providing exquisite detail of pulmonary arteries down to 4th-5th order branches.

Source: Radiographics - CT Pulmonary Angiography: Technique and Interpretation Date: 2022

What CTPA Shows

Direct Signs of PE:

1. Filling defect: Contrast outlined clot within pulmonary artery
2. Complete occlusion: Artery completely cut off by clot
3. Railroad track sign: Clot outlined by contrast on both sides
4. Peripheral wedge-shaped opacity: Pulmonary infarction

Filling Defect Patterns:

Indirect Signs of PE:

• Right ventricular enlargement: RV/LV diameter ratio >1.0
• Bowel reflux of contrast: Into IVC from right heart strain
• Pulmonary infarction: Peripheral wedge-shaped opacity, Hampton's hump
• Pleural effusion: Usually small, unilateral
• Oligemia: Lucent areas distal to clot (Westermark sign)
• Mosaic attenuation: Patchy areas of decreased perfusion

”

Key Diagnostic Point: The filling defect (clot outlined by contrast) is the definitive sign of PE. All other findings are supportive or secondary. A true PE shows contrast flowing around the clot, making it clearly visible within the opacified pulmonary artery.

Source: American Journal of Roentgenology - CT Pulmonary Angiography for Pulmonary Embolism Date: 2021

CTPA Diagnostic Accuracy

Sensitivity and Specificity:

• Sensitivity (detecting PE when present): 94-96%
• Specificity (correctly excluding PE): 94-96%
• Negative predictive value: >99% (in adequate quality studies)
• Positive predictive value: ~95% (in high pre-test probability)

Detection by Clot Location:

Limitations:

• Poor contrast opacification: Motion, breathing, timing issues
• Massive PE: May not see clots if patient can't breath-hold
• Pregnancy: Radiation and contrast concerns (though still first-line)
• Chronic PE: Harder to distinguish from acute PE
• Small peripheral clots: May be missed (subsegmental PE)

”

Clinical Controversy: The clinical significance of isolated subsegmental PE (clot in only the smallest pulmonary arteries) is debated. Many experts treat these patients with anticoagulation, but some argue for observation in low-risk patients without DVT.

Source: Chest - Subsegmental Pulmonary Embolism: To Treat or Not to Treat Date: 2023

CTPA Protocol Variations

Dual-Energy CTPA:

• Technique: Acquire data at two energy levels (80 kVp and 140 kVp)
• Advantages:
  • Iodine map shows perfusion defects (like V/Q scan)
  • Better contrast opacification with lower contrast volume
  • Can differentiate PE from other causes of perfusion defect
• Disadvantages: Higher radiation dose, not available everywhere

Low-Dose CTPA:

• Technique: Reduced tube current (mA) and/or kVp
• Indications: Young patients, serial imaging, pregnancy
• Trade-off: Slightly higher image noise but maintained diagnostic accuracy for main/lobar/segmental PE

When V/Q Is Used

Indications:

• CT contraindicated:
  • Severe iodinated contrast allergy
  • End-stage renal disease (eGFR ＜30)
  • Pregnancy (lower radiation than CTPA)
• Young patients (concern about cumulative radiation)
• Baseline abnormal chest X-ray (certain patterns)
• CT inconclusive (technical factors)

V/Q Scan Technique:

• Ventilation scan: Inhale radioactive gas (Xe-133 or Tc-99m DTPA aerosol)
• Perfusion scan: Inject Tc-99m MAA (macroaggregated albumin)
• Imaging: Planar and/or SPECT imaging
• Duration: 30-60 minutes

V/Q Interpretation

PIOPED II Criteria (Revised):

Mismatch = Ventilation normal but perfusion abnormal (classic for PE)

”

Diagnostic Limitation: V/Q scan is diagnostic only when normal or high-probability. Intermediate or low-probability results are nondiagnostic and require further testing (usually CTPA).

Source: Journal of Nuclear Medicine - PIOPED II Study Date: 2021

CTPA vs. V/Q Scan

Comparison:

”

Clinical Reality: V/Q scan is increasingly rare in emergency settings. CTPA is faster, more widely available, and provides more information. V/Q is reserved for specific situations (contraindications to CT, pregnancy, young patients).

Source: Radiology - CT Pulmonary Angiography vs. V/Q Scan for Suspected PE Date: 2022

D-Dimer

What Is D-Dimer?

• Fibrin degradation product: Released when blood clots break down
• Elevated in: PE, DVT, DIC, surgery, trauma, cancer, inflammation, pregnancy
• Highly sensitive but nonspecific: Positive in many conditions

Clinical Use:

• High negative predictive value: Normal D-dimer excludes PE in low-probability patients
• Not diagnostic: Elevated D-dimer does NOT confirm PE (nonspecific)
• Best for: Low pre-test probability (to avoid unnecessary imaging)

Assay Types:

D-Dimer Interpretation:

Low Wells score (≤4) + Normal D-dimer → PE excluded (no imaging needed)
Low Wells score + Elevated D-dimer → CTPA
Moderate/High Wells score → CTPA (D-dimer doesn't add value)

”

Practical Point: Don't order D-dimer in moderate/high-probability patients—proceed directly to CTPA. D-dimer is most useful in low-probability patients to avoid unnecessary imaging.

Source: British Medical Journal - D-Dimer for Exclusion of Pulmonary Embolism Date: 2022

Lower Extremity Imaging for DVT

Rationale: If DVT is found, treat for PE without needing chest imaging

Ultrasound for DVT:

• Indications: Symptoms of DVT, inconclusive CTPA/V/Q
• Technique: Compression ultrasound of deep leg veins
• Findings: Non-compressible vein = DVT
• Management: If DVT found, treat for VTE (PE + DVT) without chest imaging

CT Venography:

• Technique: Delayed imaging of pelvis/legs during CTPA
• Advantages: Single study for PE and DVT
• Disadvantages: Higher radiation, contrast load
• Current practice: Less common (most use ultrasound for DVT)

Chest X-Ray

Role in PE Evaluation:

• Never diagnostic for PE (clots not visible on X-ray)
• Used to: Exclude alternative diagnoses (pneumonia, pneumothorax, heart failure)
• May show:
  • Atelectasis (plate-like collapse)
  • Small pleural effusion
  • Elevated hemidiaphragm
  • Hampton's hump (rare, peripheral wedge-shaped opacity from infarction)
  • Westermark sign (rare, oligemia from clot)

Normal Chest X-Ray:

• Present in 10-40% of PE cases
• Normal X-ray does NOT exclude PE
• A normal X-ray in a patient with dyspnea should raise suspicion for PE

Risk Stratification by CT Findings

Right Ventricular Strain Signs on CTPA:

Clinical Impact:

”

Treatment Decision: CTPA findings don't just diagnose PE—they guide treatment intensity. Patients with right ventricular strain on CT may benefit from thrombolytic therapy in addition to standard anticoagulation.

Source: Circulation - Imaging-Guided Risk Stratification in PE Date: 2022

Pregnancy and PE

Why PE in Pregnancy Is Critical:

• Leading cause of maternal death in developed countries
• 5-10x increased risk vs. non-pregnant women
• Highest risk: Postpartum period (especially after C-section)
• Diagnostic challenge: Dyspnea and tachycardia are normal in pregnancy

Imaging During Pregnancy:

Pregnancy Algorithm:

Suspected PE in pregnancy
↓
Chest X-ray (exclude alternative diagnoses)
↓
CXR abnormal? → Treat for alternative (pneumonia, etc.)
↓
CXR normal? → V/Q scan (if available, lower radiation)
↓
V/Q nondiagnostic or unavailable? → CTPA (benefit > risk)

”

Bottom Line: Don't avoid necessary imaging in pregnancy. Untreated PE is far more dangerous to mother and fetus than radiation from CTPA. The fetal radiation dose is low (0.1-0.5 mSv), well below the 50 mSv threshold for concern.

Source: Obstetrics & Gynecology - Diagnosis of Pulmonary Embolism in Pregnancy Date: 2023

Pediatric PE

Rare but Serious:

• Incidence: Much lower than adults (＜1 per 10,000)
• Increased risk: Central lines, cancer, congenital heart disease, obesity, OCPs in adolescents
• Diagnostic challenge: Symptoms often attributed to asthma or pneumonia
• Imaging: CTPA first-line (radiation concern balanced against missing diagnosis)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Entity:

• Complication of PE: 0.5-5% of acute PE patients
• Pathology: Organized clots occlude pulmonary arteries, causing pulmonary hypertension
• Presentation: Progressive dyspnea over months, right heart failure
• CT findings:
  • Chronic clot appearance: Webbed, recanalized arteries
  • Pulmonary artery enlargement: >29 mm
  • Right ventricular hypertrophy
  • Mosaic perfusion: Patchy areas of decreased perfusion
• Treatment: Surgical thromboendarterectomy (potentially curable)

”

Clinical Pearl: CTEPH is potentially curable with surgery if recognized. Any patient with progressive dyspnea months after PE should be evaluated for CTEPH with CTPA and echocardiogram.

Source: European Respiratory Journal - Chronic Thromboembolic Pulmonary Hypertension Date: 2022

Before Your CTPA

Preparation:

• No fasting required (unless sedation planned)
• Clothing: Wear comfortable clothes without metal (sweatpants, t-shirt)
• Medications: Take all regular medications
• Allergy history: Tell technician about any contrast allergies
• Kidney function: May need blood test (creatinine) before contrast
• Pregnancy: Tell technician if pregnant or possibly pregnant
• Previous imaging: Bring prior chest imaging for comparison

If You Have Kidney Disease:

• Recent creatinine: Bring recent lab results
• Hydration: May be instructed to drink water before and after
• Contrast volume: May use lower volume or iso-osmolar contrast

During Your CTPA

Experience Timeline:

1. Check-in: Registration, screening questionnaire
2. IV placement: Small IV in arm or hand
3. Positioning: Lie on CT table, arms above head
4. Practice breathing: Technician coaches breath-hold
5. Contrast injection: Warm flushing sensation (5-10 seconds)
6. Scan: Single breath-hold (5-10 seconds) during injection
7. Completion: IV removed, brief observation

Sensations:

• IV placement: Brief pinch
• Contrast injection: Warm flushing throughout chest, metallic taste, urge to urinate (all normal, lasts 30-60 seconds)
• Breath-hold: May feel challenging but essential for clear images
• Scan: Painless, just loud whirring sounds

After Your CTPA

Immediate:

• Observation: 15-30 minutes (shorter if low-risk)
• Hydration: Drink water to help kidneys clear contrast (if no heart failure)
• Results: Preliminary report within hours, final report within 24 hours

What Happens Next:

Q: How quickly will I get my CTPA results?

A: Preliminary results are typically available within 1-2 hours. Your doctor receives the final report within 24 hours. In emergency situations, the radiologist communicates critical findings immediately.

Q: Does the CTPA use a lot of radiation?

A: A CTPA uses 2-5 mSv, roughly equivalent to 1-2 years of natural background radiation. While not trivial, this risk is outweighed by the benefit of diagnosing a life-threatening PE.

Q: What if I'm allergic to CT contrast?

A: If you've had a previous reaction, you may receive premedication (steroids + antihistamines) 12 hours before the scan. For severe reactions, your doctor may order V/Q scan instead.

Q: Can I breastfeed after CTPA?

A: Yes. The amount of iodinated contrast excreted in breast milk is negligible, and the infant absorbs ＜0.01% of the maternal dose. No pumping and discarding is necessary.

Q: Will I need to be admitted to the hospital if PE is found?

A: Most patients with PE are admitted for initial anticoagulation (heparin drip). However, low-risk patients with small PE and good home support may be discharged with oral anticoagulation (DOACs).

Q: Can CTPA miss PE?

A: CTPA misses ＜5% of PEs, mostly very small subsegmental clots. However, the clinical significance of these small clots is debated, and some may not require treatment.

1. CTPA is the gold standard: CT pulmonary angiogram detects PE with >95% sensitivity and specificity, providing rapid diagnosis in this life-threatening emergency.

2. Clinical suspicion first: Use Wells or Geneva score to assess pre-test probability. Low-probability patients may be excluded by D-dimer; moderate/high probability proceeds directly to CTPA.

3. CTPA provides more than diagnosis: Beyond confirming PE, CTPA stratifies risk by showing right ventricular strain, which guides treatment intensity (anticoagulation alone vs. thrombolysis).

4. V/Q scan is an alternative: Reserved for patients with contrast allergy, severe kidney disease, or pregnancy. V/Q is diagnostic only when normal or high-probability; intermediate results require further testing.

5. D-dimer excludes, doesn't diagnose: A normal D-dimer in low-probability patients excludes PE without imaging. An elevated D-dimer does NOT confirm PE (nonspecific).

6. Pregnancy requires imaging: Don't avoid necessary imaging in pregnancy. Untreated PE is far more dangerous than radiation from CTPA. Both CTPA and V/Q are relatively safe.

7. Subsegmental PE is controversial: Isolated clots in the smallest pulmonary arteries have uncertain clinical significance. Some experts treat with anticoagulation; others observe low-risk patients.

8. Negative CTPA reliably excludes PE: In a high-quality study with good contrast opacification, a negative CTPA has >99% negative predictive value—PE is effectively excluded.

”

Clinical Bottom Line: PE is a life-threatening diagnosis that requires prompt imaging. CTPA is fast, accurate, and widely available, making it the first-line test for most patients. The key is recognizing PE clinically (sudden dyspnea, pleuritic pain, risk factors) and not delaying imaging in moderate/high-probability patients. When in doubt, image—missing PE is far worse than a negative scan.

1. American College of Radiology. ACR Appropriateness Criteria®®: Suspected Pulmonary Embolism. 2023.
2. New England Journal of Medicine. "Pulmonary Embolism: Diagnosis and Management." 2022.
3. European Heart Journal. "Risk Stratification in Acute Pulmonary Embolism." 2021.
4. Radiographics. "CT Pulmonary Angiography: Technique and Interpretation." 2022.
5. American Journal of Roentgenology. "CT Pulmonary Angiography for Pulmonary Embolism: A Systematic Review." 2021.
6. Chest. "Subsegmental Pulmonary Embolism: To Treat or Not to Treat." 2023.

This article was independently researched and written based on current emergency medicine and radiology guidelines. It emphasizes the critical role of prompt CTPA in diagnosing life-threatening PE while recognizing situations where V/Q scan or alternative testing may be appropriate.